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      Drug resistance is a major obstacle in cancer chemotherapy. Better understanding 
of the mechanisms of the drug resistance can help to improve clinical treatment and 
develop new drugs. Since most anticancer drugs target the nuclei of the cancer cells, 
differential expression of nuclear proteins may play crucial roles as cancer cells 
acquire drug resistance. Thus I have carried out a comparative proteomics research 
project to study differential expression of nuclear proteins in drug resistant human 
breast cancer MCF-7 cells. Two dimensional gel electrophoresis and stable isotope 
labeling by amino acids in cell culture are used to conduct the study. Protein 
identification is acquired by peptide fingerprinting or microsequencing. Relative 
quantitation of the proteins is derived from gel comparisons and from ratios of 
labeled and unlabeled peptide pairs. A drug susceptible MCF-7 cell line and four drug 
resistant MCF-7 cell lines were examined.  The drug resistant cell lines are resistant 
to different chemotherapeutic drugs and are well characterized. The known 
mechanisms of drug resistance can not satisfactorily answer how the drug resistance 
is conferred.
      One hundred and twenty proteins have been identified from the nuclear protein 
mixture of MCF-7 cells, from which more than 90% are classically categorized as 
nuclear proteins.  Fourteen proteins are found to be significantly less or more 
abundant (• 2 fold) in MCF-7 breast cancer cell lines resistant to etoposide , 
mitoxantrone, adriamycin in the presence of verapamil by both gel comparisons and 
isotope labeling. Abundances of cytoskeleton proteins, such as cytokeratin 8, 
cytokeratin 19, septin 2, and alpha tropomyosin, are altered in common across the 
three resistant cell lines.  MCF-7 cell lines resistant to etoposide and mitoxantrone are 
more similar in protein abundance changes. Some of the proteins whose abundances 
are altered have also been reported to play important roles in resisting genotoxic 
stress in other normal and cancer cells. Their potential mechanistic contributions to 
drug resistance and implications for genetic regulation are discussed. 
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Chapter 1: Overview
      Chemotherapy is widely used to treat cancers. Drug resistance is a major cause of 
chemotherapy failure. It is important to understand the mechanisms of the drug resistance 
to improve clinical treatments. Many chemotherapy drugs target nuclear proteins in 
cancer cells. Their ultimate objective is to selectively kill the cancer cells while 
minimizing the damage to healthy cells. Nuclear proteins may play important roles in the 
development of drug resistance in cancer cells. Identification and characterization of 
differential abundance of nuclear proteins in association with drug resistance may 
provide clues for better understanding of the mechanisms of the acquired drug resistance 
in cancer cells.
      The primary objective of this research is to contribute to the understanding of the 
mechanisms of the acquired drug resistance conferred by nuclear proteins. Our specific 
aims are 1) Develop and evaluate methods to isolate nuclei and extract nuclear proteins of 
MCF-7 cells; 2) Compare expression profiles of nuclear proteins of drug-susceptible and 
drug-resistant MCF-7 cells; 3) Identify proteins whose expressions are up or down 
regulated in drug-resistant MCF-7 breast cancer cells; 4) According to the functions of 
the proteins whose abundances are changed, consider possible mechanisms of drug 
resistance.
      Two-dimension gel electrophoresis is used to provide comparative proteomics 
studies. Nuclei are isolated and nuclear proteins are extracted from cultured drug 
susceptible and resistant MCF-7cells, respectively. The nuclear proteins are then 
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subjected to 2-D gel electrophoresis and the gels are visualized. Parallel gels are analyzed 
by Compugen software and protein expression levels are compared according to the 
densitometry of the protein spots in the gels. The spots are then cut out and digested by 
trypsin. The digestion products are then analyzed by matrix-assisted laser 
desorption/ionization (MALDI) and electrospray mass spectrometers. Protein 
identifications are obtained using protein peptide fingerprinting or microsequencing and 
bioinfomatics. An illustration of the strategy is depicted in Figure 1.
       In addition, isotope labeling is also used to confirm the expression changes detected 
by gel comparison. C13 - Labeled lysine and arginine are introduced into the media in 
which drug susceptible cells are cultured. The labeled cells are mixed with drug resistant 
cells cultured in non-labeled media. Then nuclei are isolated and nuclear proteins are 
extracted. The protein mixture is subjected to 2-D gel electrophoresis and mass 
spectrometry analysis. Changes in protein abundance are determined by isotope ratios of 
labeled and unlabeled counterpart peptides. An illustration of the strategy of isotope 
labeling is depicted in Figure 2.       
      Chapter 2 introduces the background and significance of this research. Chemotherapy 
and acquired drug resistance are briefly introduced. Known mechanisms of drug 
resistance are summarized. Also I will discuss the characterization of the model 
organisms and the advantages of proteomics approach.  Application of Mass 
spectrometry is briefly introduced.
       Chapter 3 presents materials and methods. Methods are described in detail.  The 
methods include cell culture, nuclei isolation, protein extraction, 2-D gel electrophoresis, 
gel image comparison, MALDI mass spectrometry, electrospray mass spectrometry, 
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tandem mass spectrometry, protein identification and determination of peptide isotope 
ratio. 
      Chapter 4 gives results of the experiments. It shows a 2-D gel map of control MCF-7 
nuclear proteins and the proteins identified. Differentially expressed proteins detected by 
both strategies in four drug resistant MCF-7 cell lines are summarized.
      Chapter 5 mainly discusses biological implications of the changes found. For 
example, the up-regulation of nucleolin and down-regulation of PARP 1 are probably 
involved in repression of apoptosis, their potential roles in drug resistance are discussed. 
The pros and cons of both strategies are illustrated. Finally, a future perspective for this 
research is also presented.
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Figure1: Schematic of gel images comparison to identify differentially expressed 
proteins.
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Figure 2: Schematic of metabolic labeling for analysis of differentially expressed proteins 
with mass spectrometry.
Scheme 2: Metabolic Stable Isotope Labeling
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Chapter 2: Introduction
Breast cancer and chemotherapy
      Breast cancer is the most common type of cancer among women in the US and many 
other countries. According to the American cancer society, there were about 212,600 new 
cases of breast cancer diagnosed in women in the US alone in 2003. Approximately 
40,000 of theses cases resulted in death (1). Many breast cancer deaths could be avoided 
by early detection and improved treatment.
      Chemotherapy is the treatment of cancer with anticancer drugs that can kill cancer 
cells. It is sometimes the first or even the only choice to treat many cancers. More often, 
however, it is used in addition to surgery, radiation therapy and immunotherapy. 
Chemotherapy differs from surgery and radiation in that it is a systemic treatment, which 
means that the drugs can travel throughout the whole body or system instead of being 
confined or localized to one area or organ such as breast, lung, or brain. This is very 
important because chemotherapy can reach cancer cells that may have spread to other 
parts of the body. In most cases, anticancer drugs are often given in combination. The 
drugs are often administered as a pill or by injection into a vein (IV).  Either way, the 
drugs enter the bloodstream and travel throughout the body. Since anticancer drugs are 
also toxic to healthy cells, their dose that can be administered to patients is limited (2).
      More than 50 chemotherapeutic drugs are availably to treat cancers now, and many 
more are being developed and tested in clinical trials. Most chemotherapeutic drugs 
interfere with the ability of cells to grow or multiply. Based on how they work, 
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chemotherapeutic drugs are classified as the following main types: covalent DNA 
binding drugs, antimetabolites, noncovalent DNA binding drugs, inhibitors of chromatin 
function, and drugs affecting endocrine function. They often target DNA and act in the 
nuclei of the cancer cells. Many anticancer drugs have proven to be highly effective 
chemotherapeutic agents for treating a variety of types of cancers, including breast 
cancer. However, eventually they all stimulate acquired drug resistance (3-6).
Drug resistance and its known mechanisms
      Drug resistance occurs when a particular drug does not affect the cancer cells. There 
are primarily two types of resistance: intrinsic and acquired resistance. Intrinsic resistance 
occurs when the drug does not affect cells the very first time they are treated with it. 
Acquired resistance occurs after a period of anticancer drug treatment. A few cells that 
are not responsive to the drug treatment survive and multiply until most of the cell 
population becomes insensitive to the drug. Resistance occurs not only to the drug in use, 
but cross-resistance also may be acquired to other drugs, especially to the drugs having 
structural analogs or similar mechanisms of action (6).
      Drug resistance is a major obstacle in cancer chemotherapy. It accounts for the failure 
of chemotherapy to cure the majority of cancer patients and has been described as the 
single most common reason for discontinuation of a drug.  It is important to understand 
the mechanisms of the drug resistance to improve clinical treatment and develop new 
drugs. Efforts have been made to study the mechanisms over the past three decades.  The 
main known mechanisms at the molecular and cellular levels include increased drug 
efflux (7-11), decreased drug uptake (10-11), enhanced intracellular detoxification (12-
15), up-regulation of DNA repair system (15-17), inadequate drug activation (13), and 
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blocking of programmed cell death (apoptosis) (19-20).  P-glycoprotein is the most 
intensively studied single protein involved in drug resistance. It is a membrane protein 
encoded by the MDR I gene, and its overexpression is believed to be mainly responsible 
for multiple drug resistance (MDR). The role of P-glycoprotein is to activate an efflux 
pump that allows less accumulation of chemotherapy drugs in cancer cells (7). Its 
discovery has led to development of strategies to overcome drug resistance caused by its 
effect. New drugs (a third generation of P-glycoprotein inhibitors) continue to be 
developed based on this finding (21). However, the mechanisms of drug resistance are 
not well understood. It is widely accepted that the mechanisms are multifactorial and no 
single protein expression is solely responsible for acquired drug resistance (22-27).  To 
overcome drug resistance, different strategies need to be adopted for drug resistance 
conferred by different mechanisms (28-32). Better understanding of the mechanisms is 
necessary to achieve the goals of overcoming drug resistance and improving 
chemotherapy.
      The availability of rough human genome information and the recent development of 
mass spectrometry have greatly facilitated the proteomics approach as a powerful tool to 
study drug resistance in human cells (33-38).   In this study, I have compared nuclear 
proteins of drug susceptible and resistant human breast cancer MCF-7 cells using 
proteomics techniques. The nucleus, which is the largest organelle in the MCF-7 cell, is 
the control center of the cell. Its many important functions, such as RNA transcription 
and processing, DNA replication and repair, are closely related to cell growth and death
(39-40). Most chemotherapy drugs, such as alkylating agents, cross-linking agents, 
intercalating agents and topoisomerase inhibitors, target DNA or enzymes closely related 
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to DNA, and therefore act in the nucleus of the cancer cell (2). Nuclear proteins may play 
important roles in cancer cells to confer drug resistance. Changes of expression levels of 
nuclear proteins may well reveal clues about how MCF-7 cells acquire drug resistance 
(41-42). Figure 3 shows a scheme of known mechanisms of drug resistance related to 
nuclear proteins. Inhibition of apoptosis and enhancement of DNA repair have been the 
focuses of the mechanisms of drug resistance related to nuclear proteins. Change of drug 
targets, such as mutation of topoisomerase I, has also been reported (22). Recently, defect 
of DNA repair has been linked to drug resistance in Plasmodium falciparum (43). This 
may also apply to drug resistance in cancer cells. The defect of DNA repair may make 
the cancer cells more tolerable to mutations, which may cause drug resistance.
10
Figure 3: Known mechanisms of drug resistance related to nuclear proteins. Adopted 
from Dr. Michael M. Gottesman, Annua. Rev. Med. 2002. 53:615-27.
Enhancement of repair of DNA damage
Inhibition of apoptosis
Change of drug targets
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Model organisms
Drug susceptible MCF-7 cells (control)
      MCF-7 cell lines are used in present research for analysis of their nuclear proteins. 
Drug- susceptible MCF-7 cell line (MCF-7/WT) is used as the control. Because of its 
stability, the cell line has been widely used to study the effects of anticancer drugs since 
it was established from a pleural effusion of patient with metastatic mammary carcinoma 
in 1973. It tests positive for cytoplasmic estrogen receptors and is capable of forming 
domes (44). Four drug-resistant MCF-7 cell lines were studied are all derived from this 
parental cell line. 
MCF-7 cells resistant to VP-16 (MCF-7/VP)
      The first drug resistant cell line is VP-16 resistant MCF-7 cell line (MCF-7/VP), 
which was developed in Dr. Ken Cowan’s laboratory in NIH by selection during culture 
in  increasing  concentrations etoposide. It is reported to be 28-fold resistant to etoposide 
(VP-16), 21-fold resistant to teniposide and 9-fold resistant to adriamycin (45).  The 
chemical structure of etoposide is shown in Figure 4. Etoposide is clinically used for 
treatments of small cell lung cell cancer and refractory testicular tumors.  Its actions 
involve locking topoisemerase II in a cleavable complex and activating a Ca/Mg 
endonuclease to trigger apoptosis. Schneider et al characterized resistance in this VP-16 
resistant cell line as multifactorial (45).  No overexpression of P-glycoprotein was 
detected in this cell line. The levels of topoisomerase II and its sequence were similar in 
both cell lines. However, topoisomeras II from VP-16 resistant cells appeared to be 7-
fold less sensitive to drug- induced cleavable complex formation in whole cells and 3-
12
fold less sensitive in the nuclear extract, compared to control MCF-7 cells. Reduction in 
intracellular drug concentration as a consequence of overexpression of the multiple drug 
resistance related protein (MRP) was suggested as a cause of the resistance but the 
analysis was not conclusive (45-46). This indicates that other proteins might contribute to 
the insensitivity to the drug in the VP-16 resistant cells.  In addition, a study by Marion 
Gehrmann in our lab found no significant expression changes of cytoplasmic proteins in 
VP-16 resistant cells (unpublished data).  These observations led us to focus on the 
nucleus and other organelles.
MCF-7 cells resistant to mitoxantrone (MCF-7/MX)
      A second drug resistant MCF-7 cell line (MCF-7/MX) was also provided by Dr. Ken 
Cowan. It was isolated by serial passage of the parental control MCF-7 cells in stepwise 
increasing concentrations of the anthracenedione mitoxantrone. MCF-7/MX cells are 
approximately 4000-fold resistant to the cytotoxic effects of mitoxantrone, and 50 to 180-
fold cross-resistant to analogs of camptothecin, a known topoisomerase I poison. They 
are also approximately 10-fold cross-resistant to adriamycin and etoposide (47-48).  
Intracellular accumulation of radio-labeled mitoxantrone was markedly reduced in MCF-
7/MX cells relative to that in control MCF-7 cells. This decrease in introacellular drug 
accumulation can be reversed by sodium azide and 2, 4-dinitrophenol, suggesting an 
energy-dependent process associated with enhanced drug efflux (49). Mitoxantrone 
resistance in MCF-7 cells is not mediated by MDRI, MRP.  Functional assays and 
western blot analysis for topoisomerase I and topoisomerase II have revealed no 
difference in activity or protein levels of topoisomerase I and topoisomerase II in MCF-
7/MX cells (46, 48). Recently, A 95 kDa multidrug resistant transporter, encoded by the 
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mitoxantrone resistance gene, MXR, also termed breast cancer resistant protein (BCRP),
was found overexpressed in the cell line (8, 50-55).  Mitoxantrone is most commonly 
used in treatment of leukemia, lymphomas, breast cancer, and ovarian cancer. Figure 5 
shows the chemical structure of mitoxantrone. Its action involves inhibiting the strand 
passing activity of topoisomerase II (47).  The mechanisms of drug resistance in this cell 
line are also considered multifactorial. Chromosome transfer experiments show that at 
least one genetic event is dominant (59). 
MCF-7 cells resistant to adriamycin in the presents of verapamil (MCF-7/AdrVp)
        The third drug resistant MCF-7 cell line (MCF-7/AdrVp) was provided by Dr. 
Douglas Ross from The University of Maryland Medical School. It was isolated by 
selecting the viable human breast cancer MCF-7 cells with incremental increases of 
adriamycin (Adr) in the presence of verapamil. It is 900-fold resistant to Adr, does not 
overexpress Pgp, and does not exhibit decreased accumulation of Adr because of the 
presence of verapamil (54). BCRP was also found overexpressed in the cell line.  It 
appears to play a major role in the multidrug resistance. However, BCRP overexpressing 
transfectant MCF-7 cells and MCF-7/AdrVp cells differ in that the degree of drug 
resistance in the latter is great than in the transfected cells. It is possible that expression 
of other proteins is required (55-61).  Figure 6 shows the chemical structure of 
adriamycin (Adr). Its generic name is doxorubicin.  Adriamycin is a glycoside isolated 
from culture of Streptomyces peucetius var. caesius. It is an anthracycline antibiotic with 
cytotoxic actions. Several mechanisms have been proposed to explain for the anticancer 
actions of adriamycin, including free radicals mediated cytotoxicity through redox 
cycling of Adr semiquinone radical, interaction of DNA, stabilization of topoisomerase 
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II-DNA complex and inhabitation of RNA and protein synthesis. It is well accepted that 
its ability of generating free radicals is of dominance in its anticancer actions. It is 
clinically used to treat hematological malignancies such as acute leukemias and 
lymphomas, and is also used to treat solid tumors including breast, lung, and thyroid 
cancer. Its clinical use is limited by its cardiotoxicity(54). Verapamil is a calcium channel 
blocker, which acts to overcome Pgp-mediated drug resistance as a competitive inhibitor 
of drug binding and efflux (54). Its chemical structure is shown in Figure 7.
MCF-7 cells resistant to adriamycin (MCF-7/Adr)
      The fourth drug resistant cell line MCF-7/Adr was first selected in stepwise 
increasing concentration of adriamycin in 1986 (62).  It has been used as a model to study 
drug resistance in cancer cells. It is 192-fold resistant to adriamycin and has distinctive 
biochemical characteristics (63-65).   A DNA fingerprint study has indicated that this cell 
line is far apart from the control cell line (64). It has a full-length caspase-3 gene which is 
missing in control MCF-7 cell line (66). Questions were raised about the identity and 
origin of the cell line recently (66-68). Study in our lab has shown it has a dramatically
different expression profile of cytosolic proteins from that of control MCF-7, MCF-7/VP 
and MCF-7/AdrVp cell lines (69). This suggested that it was most likely that its 
expression profile of nuclear proteins was also distinctive. It was used as a possible 
positive control to analyze changes in abundance of the nuclear proteins. Characterization 
of its nuclear protein expression profile can also help clarify its identity and origin.
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Proteomics and comparative proteomics
      Proteome refers to the entire complement of proteins of a certain type of cell or 
organism. The term “proteome” was first coined in 1995, as an equivalent to genome (70-
71). Proteomics is generally defined as the systematic analysis of complex protein 
mixtures under certain conditions.  Actually, it dates back to the mid 70’s of the last 
century with the independent introduction of 2-D gel electrophoresis, which separates 
proteins first by their isoelectric points and then by their sizes. In the beginning, about 
300 proteins could be separated by 2-D gel electrophoresis (72-73). Now, with refined 
techniques, more than 10,000 protein spots can be separated with high reproducibility 
(74-75). This has the potential to reveal almost all proteins of a specific cell type, its 
proteome.  
       The proteomics approach, which directly measures protein expressions, is more 
meaningful to study biological functions of proteins than the genomic approach (76).  
Unlike the genome, which is static, proteome is highly dynamic. The genome indicates 
all the proteins that may be expressed, but not necessarily the proteins that are expressed 
(77). Proteins undergo posttranslational processing and modification, such as 
phosphorylation, acetylation, ubiquititation, or glycocylation, which strongly influence 
their functions but can not be deduced from the DNA or RNA sequence. These 
modifications may be detected by proteomics techniques (78-80). It has been 
demonstrated that RNA levels do not always correspond to protein expression levels (81-
83). The human genome has about 30,000-40,000 genes, however, the number of proteins 
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is much larger (33-34). Traditional biological research approaches, which usually study 
one or a few proteins at a time, can not deal well with complicated mixtures. In the 
nucleus of MCF-7 cells, there are several thousands of proteins, many of which may be 
related to drug resistance (37-38).  A proteomics approach is the best choice to study it.
        Comparative Proteomics analyzes relative protein expression in two or more 
samples (83-84). The samples are taken from organisms in the control and altered states. 
In this research, 2-D gel electrophoresis is used in combination with mass spectrometry to 
identify and analyze differentially expressed nuclear proteins in drug resistant MCF-7 
cells.  Protein identifications are acquired by peptide mass mapping and sequence 
tagging. Protein differential expression is determined by contrasting the position and 
density of spots in two-dimension gels. Stable isotope metabolic labeling is also used to 
determine protein differential expression, according to the isotope ratios of the labeled 
and unlabeled peptide pairs from drug susceptible and resistant MCF-7 cells. The results 
from both gel comparison and metabolic labeling are compared and evaluated.
Two-dimensional gel electrophoresis
      Two-dimensional Gel electrophoresis is a combination of two types of gel 
electrophoresis: isoelectric focusing (IEF) and sodium dodecyl sulfate- polyacrylamide 
gel electrophoresis (SDS-PAGE) (71-72). IEF separates proteins by their ioselectric 
points using a pH gradient across a high electric potential. The isoelectric point of a 
protein is a characteristic pH at which its net charge is zero.  The protein sample is 
dissolved in a small volume of rehydration buffer containing nonionic detergent, DTT 
and denaturing reagent urea. The rehydration buffer solublizes, denatures and dissociates 
all the peptide chains but leave the intrinsic charge of the proteins unchanged. In an 
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electric field, the protein will move to the position of its isoelectric point in the pH 
gradient and become immobilized. A pH gradient can be formed with a mixture of 
ampholytes, which are aliphatic polyaminopolycarboxylicacids with different pIs.  
Immobilized pH gradient (IPG) gel strips are most commonly used for isoelectric 
focusing now.  IPG gel strips are made from acrylamide derivatives that have different 
acidic and basic side chains on them. Creating different mixtures of these acrylamides 
derivatives and polymerizing them can make polyacrylamide gels with different 
immobilized pH gradient ranges and with resolution of up to 0.01 pI units. They are very 
reproducible and commercially available (86-89).
      The second dimension in 2-D gel electrophoresis is SDS-PAGE.   In this step the IPG 
gel strip containing the separated proteins is subjected to electrophoresis again, but in a 
direction at right angle to that used in the first dimension. This method separates proteins 
according to their molecular weights. SDS is a detergent used to denature proteins and 
eliminate positive charges on proteins. The first dimension gel strips are soaked in SDS 
and then placed on one edge of a SDS polyacrylamide gel slab, through which each 
protein migrates to form a discrete spot when a voltage is added (90-93). 
       As a result, 2-D gel electrophoresis can provide protein mixture as arrays of spots on 
a polyacrylamide gel. The spots can be visualized by several different gel staining 
methods. These methods include silver staining, fluorescent staining, and Coomassie blue 
staining, which is used in this study. Coomassie blue is an organic dye that binds to 
proteins. Proteins will be stained in proportion to the amount of their basic and aromatic 
amino acids and the amount of sample in the spot.
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      Protein quantitation can be determined based on density of the reagents binding to the 
proteins. Manual or computerized inspection can compare protein differential expressions 
in parallel gels. Computer software can make digitized images of the gel arrays and 
evaluate them. 
Mass spectrometry
      A mass spectrometer is an instrument that measures the mass-to-charge ratio of the 
ions formed from the sample molecules.  It can be described in five parts: inlet, ion 
source, mass analyzer, detector, and recorder. The inlet is used to introduce sample from 
room pressure into the ion source under vacuum. The ion source converts the sample 
molecules into sample ions. The mass analyzer controls the movement of the sample ions 
and allows them to be separated according to their masses. The detector detects the 
arrival of mass-separated ions and converts them into a stronger electric signal. The 
recorder creates the mass spectrum. Different combinations of ion source, mass analyzer 
and detector can make different types of mass spectrometers (94). 
Mass spectrometry has been a powerful analytical technique to identify, quantify 
compounds and elucidate their structures and chemical properties since it was invented
(94-95). However, its application to macromolecules was limited before the two 
breakthroughs were made in ionization methods: matrix-assisted laser 
desorption/ionization (MALDI) and electrospray ionization (ESI) (97-99). These methods 
solved the technical difficulty of generating ions from nonvolatile macromolecules such 
as proteins or peptides without significant fragmentation for further analysis. They were 
referred to as “soft” ionization methods because fragmentation is minimal and some 
noncovalent interactions may be preserved during the ionization process under specific 
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conditions. These methods rapidly gained popularity and catalyzed the revolution of 
protein analysis.  
     MALDI was first developed by two groups, Karas and Hillenkamp from US and
Tanaka from Japan in 1987(97-98). This ionization technique is performed by 
cocrystalizing the sample in a chromaphoric organic matrix and irradiating analyte-matrix 
crystals with a pulsed UV laser. The matrix has a strong absorbance at the laser 
wavelength. When the laser strikes the crystals on the target surface, the crystals were 
electronically exploded. Photo-excited matrix molecules undergo reaction with the 
analyte in the plume. As a result, the analyte molecules become ionized predominantly by 
simple protonation, leading to the formation of [M+H] + type ions. Sometimes multiply 
charged ions, dimers and trimers can also be formed. Negative ions are formed from 
reactions involving deprotonation of the analyte by the matrix to form [M-H] - and from 
interactions with photoelectrons to form the [M] - radical molecular ions. The ionized 
analyte is then pulsed into the mass spectrometer for analysis. MALDI has been used in 
conjunction with different kinds of mass spectrometers; such as Fourier transform ion
cyclotron resonance (FT-ICR), quadrupole ion trap, and time of flight (TOF) mass 
spectrometers (100). MALDI-TOF is commonly used for protein and peptide analyses
(101-102). 
     ESI was developed into modern-day ionization technique by Fenn in 1980s (99). ESI 
is performed by spraying the conducting sample solution across a high potential 
difference from a needle into an orifice in the interface. The sample solution forms a 
finely charged mist of analyte and solvent and then heat and gas flows are used to 
desolvate the ions in the sample solution to yield highly charged analyte ions. This 
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method can produce multiply charged ions with the number of charges tending to 
increase as the molecular weight increases.  Analytes with a mass in excess of the mass 
range of the mass spectrometry can still be detected since mass spectrometers determine 
the mass of the sample as a function of mass-to-charge ratio. This method can also be 
readily coupled to HPLC and other liquid separation techniques. A refined version of 
electrospray, nanospray, was developed in 1996 (103). It actually is a miniaturized 
electrospray, which uses a needle with much smaller diameter than that used in 
electrospray and nL/min flow rates. Nanospray is more sensitive than electrospray since 
the process is concentration dependent. ESI has been successfully used with a variety of 
mass spectrometers, including triple quadrupole, quadrupole ion trap and quadrupole time 
of flight (104). 
       Tandem mass spectrometry (MSMS) has become available in recent years for the 
analysis of biological samples (105). A tandem mass spectrometer can be regarded as two 
mass spectrometers in series connected by a chamber that can be used to activate 
fragmentation of ions. This chamber is known as a collision cell. A sample can be 
scanned and sorted in the first mass spectrometer, and then a selected ion of a molecule 
can be broken into pieces of product ions, which can be analyzed in the second mass 
spectrometer. For tandem mass spectrometers in conjunction with ESI, fragment ion 
spectra are generated by collision-induced dissociation (CID). The peptide ion of interest 
is selected and fragmented in a collision cell and the fragment ion spectra are recorded. 
Tandem mass spectra generated by the fragment of peptide ions by low collision energy 
CID are dominantly fragment ions resulting from cleavage at the amide bonds. A 
schematic of peptide fragmentation by low collision energy CID is shown in Figure 8.  If 
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the positive charge in association with the parent peptide remains on the amino-terminal 
side of the peptide fragment, it is termed a b ion. If the charge remains on the carboxyl-
terminal side of the broken amide bond, it is termed a y ion. The mass differences 
between b ion series or y ion series correspond to the masses of amino acids.  A partial or 
whole amino acid sequence tag of the peptide can be obtained from the mass difference. 
According to the spectra collected from the parent and product ions, structure information 
may be revealed about the precursor molecule (105-107). 
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Figure 8: Schematic of peptide fragmentation by low collision energy CID.
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Protein identification
      Traditionally, proteins have been sequenced and identified most frequently by Edman 
degradation of the proteins or their peptide fragments. The partial sequences could be 
used for generation of probes of the gene coding for the protein from a gene library, and 
sometimes were used to assemble the complete protein sequence from overlapping 
fragments.  After the sequencing of human genome and other genomes, the increasing 
sequence database made it possible to use short sequences of peptides to identify 
proteins. This was done by correlating experimental information with sequences in the 
database using search algorithms.  Mass spectrometry was suitable to provide the 
required data (106). 
      There are two main strategies to identify proteins by mass spectrometry: peptide mass 
mapping and microsequencing.  Peptide mass mapping is also referred to as peptide mass 
fingerprinting. Its idea was first introduced by Cleveland in 1977 et al. and was 
incorporated with mass spectrometry in 1993 (108-109). The principle is that proteins of 
different amino acid sequence will generate different mixtures of proteolytic peptides, 
whose masses constitute mass fingerprints unique for specific proteins. A mass spectrum 
of a mixture of peptides can be generated following site-specific proteolytic cleavage of a 
protein. Then the masses of the peptides are used for database searching.  Each protein in 
database is theoretically “digested” to produce a list of peptide masses that is compared to 
the list of experimental masses. A search algorism is used to compare the set of 
experimental peptide masses against the sets of theoretical masses in the database. If 
certain criteria are met to produce qualified matches, a protein can be identified. Many 
variables such as pI, molecular weight, and post-translational modifications can be taken 
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into account to help the identification. Peptide mass mapping depends on the correlation 
of several peptide masses from the protein with corresponding masses calculated from the 
database. To get a confident identification, enough peptide masses are needed (110-112). 
This method cannot be used to identify mixtures of proteins. It does not work well with 
small proteins either, since small proteins may not yield enough peptides for analysis. 
          The other strategy to identify proteins by mass spectrometry is microsequencing. It 
depends on tandem mass spectrometry to generate spectra that contain sequence 
information. This sequence information, in combination with the peptide mass, and the 
masses before and after the tag, is used to search a database to identify the precursor 
protein of the peptide (105-107). Other information on the protein, such as post-
translational modification, molecular weight, pI etc., can be taken into account of the 
search algorism (112-113). A high-quality sequence tag can easily identify the protein 
confidently. The more sequence tags obtained for a protein, the more confident the 
identification is. This method can be used to identify a single protein that cannot be 
identified by peptide mapping, and can also be used to analyze peptides mixture of 
different proteins.
Stable isotope labeling by amino acids in cell culture
      For comparative proteomics, stable isotope labeling by amino acids in cell culture, 
has become a popular technique to identify differentially expressed proteins. Using 
metabolic labeling, two sets of cells are grown in amino acid-deficient culture media, 
supplemented with, for example, 12C6- or 
13C6-labeled amino acids. The proteins in the 
two sets of cells contain either the light or the heavy isotopes. The two sets of cells can 
then be mixed in equal ratios and subjected to protein isolation and further analysis. The 
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mass difference between unlabeled and labeled proteins is expected to have no effect on 
the sample processing. Upon digestion of the proteins, unlabeled and labeled peptides 
have the same chemical properties and are supposed to behave identically during 
extraction, desalting and ionization. The ratio of intensities of the light and heavy peptide 
pair is measured in mass spectrometry to provide relative abundance information for the 
peptide pair and their original proteins (114-115). 
     In the present research, 13C6-labeled arginine and 
13C6-lysine are introduced into the 
drug susceptible MCF-7 cells, which are mixed in turn with the other three drug resistant 
cells. Since tryptic digestion of proteins produces arginine and lysine terminating 
peptides, all peptides except the original C-terminus, are labeled at C-terminus. Thus 
peptide pairs of 6-dalton difference are generated and are easily detected by mass 
spectrometry. 
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Chapter 3: Materials and methods
Materials
      The protein isoelectric focusing (IEF) cell, Protean II Xi cell, Immoblized pH 
gradient (IPG ) strips (17cm,pH3-10NL) , IPG buffer ( pH 3-10NL), Protean II ready gels 
(8-16% Tris-HCl  precast gel 193x183x1.0 mm, IPG COMB), microbiospin  P6 columns 
in Tris.HCl buffer and biosafe stain , phosphate buffer saline solution(PBS),were 
purchased from Bio-Rad (Hercules, CA). Nuclei Pure Prep Nuclei Isolation Kit (Cat No: 
NUC-201), propodium iodide, micrococcal nuclease,  trypan blue, urea, thiourea, 
CHAPS, ethylenediaminetetraacetic acid (EDTA), dithiothreito (DTT), CaCl2, 
NH4HCO3, NaCl, Eagle’s minimal media (MEM), fetal bovine serum (FBS), 
iodoacetamide, TrismaBase, sodium dodecylsulfate (SDS), glycerol were from Sigma 
Co. (St. Louise, MO). Modified porcine trypsin (sequence grade) was purchased from 
Promega (Madison, WI). ZipTip C18 is from Millipore (Billerca, MA). 
13C6-lysine and 
13C6-arginine were purchased from Cambridge Isotope Laboratories (Cambridge, MA).
Cell culture
MCF-7 cells were cultured in MEM (Sigma, St. Louis, MO) with 10% of FBS 
(Sigma) and 1% penicillin streptomycin. Isotope labeled control MCF-7 cells were 
cultured in the same MEM except that the essential amino acids lysine and arginine were 
replaced with their isotopic c 13C6 counterparts (U-13C6, Cambridge Isotope 
Laboratories, Cambridge, MA). Dialyzed FBS were used, from which non-labeled lysine 
and arginines have been removed. Isotope labeled control MCF-7 cells were processed 
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and checked separately to make sure that isotope labeled amino acids were incorporated 
into the proteins in the nuclei before mixing with resistant cells. Every 6 months, the drug 
resistant cell lines were subjected to a reselection cycle of three passages with culture 
medium containing increased concentrations of the appropriate drugs.
Isolation of nuclei and preparation of nuclear proteins
      A nuclei isolation kit (Sigma, Product No. NUC-201) was used to isolate and purify 
MCF-7 nuclei, according to user instructions with slight modifications. Cultured MCF-7 
cells were harvested at 95% confluence. The cultures were treated with trypsin to cleave 
and centrifuged at 500 g, then washed twice with PBS.  The cell pellets were weighed  
and added  to hypotonic lysis buffer in a ratio of 1g cells to 10 ml buffer with 0.5 % 
Triton X-100. Then they were vortexed for 10 seconds and were set on ice for 5 minutes.  
The cell lysate was stained with 0.4% trypan blue solutions (Sigma) to monitor if the 
cells were completely broken. If no intact MCF-7 cell could be observed under a light 
microscope, then the cell lysate was centrifuged through a sucrose cushion at 30,000g for 
45 minutes to purify the nuclei. The nuclei pellets were washed twice with nuclei storage 
buffer and spun down at 500g. A small sample of the nuclei was observed under a 
fluorescence microscope stained with propodium iodide, the nuclei were weighed and 
nuclear protein extraction solutions were added in a ratio of 4ml solution for every 1 
gram of nuclei.  The nuclei pellets were resuspended in the NaCl buffers described earlier 
and vortexed vigorously for 15 seconds every 10 minutes, for a total of 40 minutes on ice. 
Then the suspension was centrifuged at 16000g for 10 minutes. The supernatant fraction 
was immediately transferred to new pre-chilled tubes and snap-frozen in aliquots with 
liquid nitrogen and stored at –80 0C (116). 
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Protein assay
      Bio-Rad DC protein Assay kit was used to measure protein concentration of the 
nuclear protein extract. The DC Protein Assay is compatible with the chemicals used in 
protein extraction. A modified assay protocol was used to perform the assay. A series of 
0, 25, 50, 75,100, 125 ug/ml sample of bovine serum albumin (BSA) were used to make 
standard curve. Absorbances were read at 750nm using a Beckman DU 530 life science 
UV/Vis spectrometer. The protein concentrations of samples were calculated based on 
their absorbances and dilution fold.
2-D gel electrophoresis
      Three hundred and fifty micrograms of proteins was used to conduct 2-D gel 
electrophoresis. Before loading the first dimension strip, the protein sample was desalted 
with Biospin-6 spin columns (Biorad, Hercules, CA) and added to three and a half 
micrograms of micrococcal nuclease and incubated at 37 0C for 30 minutes to eliminate 
possible DNA or RNA contamination. The sample was then dried by Speed Vac and 
320ul of rehydration buffer was added, which contained 7M urea 2M thiourea, 2% chaps 
50mM DTT and 1% of IPG buffer (Pharmacia, Piscataway, NJ). The solution was 
incubated at room temperature for 1 hour. Seventeen cm pH3-10 NL ReadyStripTM  IPG 
strips (Biorad, Hercules, CA)) were used for the first dimension isoelectric focusing (12 
hours rehydration, 60000hv), 193x183x1.0mm, 8-16% Tris-HCl IPG COMB precast gels 
(Biorad) were used for the second dimension SDS polyacrylamide gel electrophoresis (16 
mA for 30 minutes and then 24 mA for 4 hours and 40 minutes). At the end of the run, 
the gels were removed and soaked in a solution containing acetic acid/methanol/water 
(5:45:50, v/v/v) for at least 1 hour for fixation, followed by three washes for 5 minutes in 
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water. Staining was performed with Bio-Safe colloidal Coomassie blue G-250 (Biorad, 
Hercules, CA) for 2 hours. The gels were then rinsed by water until the desired contrast 
was achieved for densitometric image analysis.
Analysis of gel images
      A GS-800 calibrated densitometer (Biorad, Hercules, CA) was used to visualize 
Coomassie stained gel slabs. After the gels were scanned, the images were exported as 
TIFF files.  The TIFF files of 2-DE images of control and drug resistant MCF-7 nuclear 
proteins were compared using Compugen Z3 software (Compugen Ltd., Tel Aviv, Israel). 
In each gel, the intensity of a spot was measured and recorded. It represents the sum of all 
pixels in the spot boundary after subtracting the background level values. For 
comparative analysis, relative intensity of each pair of matching spots was measured and 
relative abundance and differential abundance values were displayed. The image 
comparison was checked manually to exclude any error in matching pairs of spots. Spots 
of interest were also examined using “zoom” images. Figure 9 shows a schematic of gel 
images comparison using Compugen software.
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Figure 9: Schematic of gel image comparison by densitometry.
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In-gel tryptic digestion and peptide desalting
      After gel image analysis, the spots of interest were then excised.  The spots could be 
stored at –80 0C at this time or directly subjected to in-gel digestion.  Before digestion, 
the spots were cut into roughly 1-mm3 cubes, and transferred to clean 1.5 microfuge 
tubes. The gel particles were washed with water and water/acetonitrile 1:1 (v/v) (one 
change, 15 minutes/change). Solvent volumes used in the washing step roughly equaled 
two times the gel volume. Then all the liquid was removed, and enough acetonitrile was 
added to cover the gel particles. After the gel pieces shrank, acetonitrile was removed and 
0.1 M NH4 HCO3 was added to rehydrate the gel pieces for 5 minutes. Next, an equal 
volume of acetonitrile was added and incubated for 15 minutes, followed by removing all 
liquid and drying down the gel particles in a vacuum centrifuge. Afterward 10 mM 
DTT/0.1 M NH4 HCO3 was added and incubated for 45 minutes at 56 
0C to reduce the 
proteins. After reduction, the tubes were chilled to room temperature, and excess liquid 
was removed and replaced by roughly same volume of freshly prepared 55 mM 
iodoacetamide / 0.1 M NH4 HCO3 for alkylation. The tubes were incubated for 30 
minutes at room temperature in the dark followed by removing the iodoacetamide 
solution. The gel particles were washed with 0.1 M NH4 HCO3 and acetonitrile as 
described before followed complete drying down in a Speed Vac. Then 50mM NH4
HCO3 , 5 mM CaCl2 and 12.5ng/ul sequencing grade modified trypsin ( Promega, 
Madison, WI) were added to rehydrate the dried gel particles at 4 0C  (ice bucket). 
Enough trypsin solution should be added if the initially added volume was absorbed by 
the gel pieces. After 45 minutes incubation on ice, the remaining enzyme supernatant was 
removed and replaced with 5-20ul of 50mM NH4HCO3, 5 mM CaCl2 depending on the 
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sizes of the gel spots. The tubes were then incubated at 37 0C in a water bath overnight. 
After overnight  digestion, a sufficient volume of 25 mM  NH4 HCO3  was added to cover 
the gel pieces and incubated for 15 minutes, followed by adding the same volume of 
acetonitrile  and incubation  for 15 minutes. After the supernatant was recovered, the 
extraction was repeated two times with 5% formic acid and acetonitrile (1:1, v/v). All the 
extracts from same gel spot were pooled and dried down in a Speed Vac. The dried 
extract samples could be stored at -80 0C or redissolved with 10  ul  0.1% TFA water for 
desalting with ZipTip C18 pipette tips ( Millipore, Bellerica ) (117-118). 
      To desalt  the peptide extracts, a wetting solution (50% acetonitrile in water) was first 
aspirated and dispensed into the tips twice, followed by two times of addition and 
aspiration of equilibration solution ( 0.1 % TFA water). The redissolved peptide extracts 
were then aspirated into the tips 10 cycles for maximum binding of the complex 
mixtures. Next, five cycles of wash solution (0.1 % TFA in water) were aspirated into 
tips and dispensed to waste. Finally 5 ul of 0.1% TFA, 70% acetonitrile was used to elute 
the peptides. The eluted samples could be used directly for mass spectrometry analysis 
with  an AXIMA-CFR MALDI –TOF (Kratos, Chestnut Ridge, NY)  mass spectrometer 
or  would be dried by  Speed Vac and redissolved in  acetic acid/methanol/ 
water(2:49:49, v/v/v) for analysis using electrospray on a hybrid quadrupole time-of-
flight instrument(QSTAR/Pulsar, Applied Biosystem, Foster City, CA). 
Mass spectrometry analysis and protein identification
  Mass spectra are acquired with an AXIMA-CFR (Kratos, Chestnut Ridge, NY) mass 
spectrometer and an API QSTAR Pulsar Qq-TOF (Applied Biosystem, Foster City, CA) 
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instrument.  Protein identifications were obtained from peptide mass fingerprinting and 
microsequencing. 
      Routinely, the samples were first analyzed using the MALDI mass spectrometer. The 
instrument was operated in the reflectron positive ion mode. The laser power was set at 
45-50 on the manufacturer’s scale of 0 to 180. The monoisotopic peaks of trypsin 
autolysis products, m/z 842.51 and 2211.11, were used for internal calibration of each 
spectrum. If these trypsin autolysis peaks were not detected, melletin and angiotensin II 
were used as external calibrats. An aliquot of 0.5ul of sample solution was put on the 
plate and covered with 0.5 ul of 50 mM alpha-hydroxycinnamic acid in 0.1% TFA, 70% 
acetonitrile, then dried before being put into the instrument. Spectra were recorded by 
accumulating 50-100 laser shots, depending on the quality of the sample.  The data from 
the spectra were used to identify proteins by peptide mass fingerprinting. Peptide mass 
fingerprinting uses residue-specific peptides mass to match against theoretical peptide 
libraries generated from the human genome to create a list of likely protein 
identifications. We used Mascot search programs from www.matrixscience.com  to 
obtain protein identifications for our experiments. The NCBI and SwissProt databases 
were searched. If certain criteria were met, the protein was considered to be identified 
confidently. An illustration of protein identification by peptide mass mapping is depicted 
in Figure 10. Mascot search results show candidate proteins and scores based on 
probability analysis. Our identifications were confirmed manually by checking for 
consistency in the pIs and molecular weight values provided by the 2-D gel array. If no 
conclusive identification could be acquired, the sample would be analyzed using 
nanospray tandem mass spectrometry to identify proteins by microsequencing.
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      Protein identification using microsequencing involves using tandem mass 
spectrometry to obtain sequence information for one or several peptides of the protein to 
match against theoretical sequences generated from the protein database. The instrument 
used for acquiring tandem mass spectrometry was a hybrid quadrupole time-of -flight 
(TOF) mass spectrometer, API QSTAR Pulsar Qq-TOF. The instrument was operated in 
two modes. The first was the MS mode, in which ions entered the instrument from the 
nanospray source and passed through two quadrupoles. The ions were then pulsed into 
the TOF tube and m/z values were measured. The resulting mass spectrum showed the 
mass-to-charge ratios of all the analytes entering the mass spectrometer at that time. 
Typically, 2 ul of the peptide solution in acetic acid/methanol/ water (2:49:49, v/v/v) was 
loaded into a capillary tip (Protana, Odense, Denmark) and mounted into the nanospray 
source. Spray voltage was set at 900V. MS scan range is from 350-1200m/z.  The second 
mode of operation was MS/MS, or collisional activation with a product ion scan. The 
ions of interest (precursor ions) were isolated by the first quadrupole, and the more 
abundant ions are automatically selected to pass into the second quadrupole, where they 
were fragmented by collision with an inert gas such as nitrogen. The fragmented products 
(product ions) are then pulsed into the TOF analyzer and measured. Product ion spectra 
are recorded. Under low energy collision, peptide ion fragmentation occurs typically 
between each amino acid residues, thus generating b-ion and y-ion series. A partial de 
novo sequence can be obtained for each precursor peptide ion, which is used for database 
search. Again candidate proteins are listed by the bioinformatics program along with 
probabilities of correct identifications. Multiple microsequences improve the reliability of 
the protein identification. We usually chose 3-4 doubly charged peptides ions for 
39
sequencing. We used the BioExplore program integrated with the instrument to identify 
proteins using the resulting MS/MS spectra.  An illustration of protein identification by 
microsequencing is depicted in Figure 11. Other database search programs such as 
TagIdent (http://www.expasy.ch) and MS-Blast (http://www.dove.embl-
heidelberg.de/blast2/msblast.html) were used as necessary.
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Nuclear Proteins of MCF-7  
Figure 10: Schematic of protein identification by peptide mass fingerprinting.
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Figure 11: Schematic of protein identification by peptide microsequencing.
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Stable isotope labeling analysis
      In our stable isotope labeling experiments, 13C6-lysine and 
13C6-arginine were 
introduced into the control MCF-7 cells during cell culture, and these were mixed with 
drug resistant cells in a ratio of approximately 1:1. Incorporation of isotopes was 
evaluated to quantitate the extent to which of the lysine and arginnine were replaced by 
13C6-lysine and 
13C6-arginine counterparts in the nuclear proteins of control cells. The 
nuclear protein expression profile of MCF-7 cells cultured in isotope labeling media was 
compared using image analysis with that of MCF-7 cells cultured in regular media. Since 
protein samples were first separated by 2-D gel electrophoresis, six- Dalton -separated 
peptide pairs were easily obtained in the spectra of the mixture. Peptides from proteins 
known from 2-D gel images not to be modified were examined to calibrate the mixing 
ratios of cells. To avoid the effects of overlapped peptides, peaks of ions having no 
adjacent peaks which were different by around 6 Daltons were chosen to calculate 
relative abundance. Relative abundance (RA) is defined as peak area of unlabeled peptide 
over that of labeled peptide. However, isotope incorporation percentage must be taken 
into account. Supposing the incorporation percentage of 13C6-lysine or 
13C6-arginine in a 
particular peptide was X%, the revised relative expression was as follows,
RA= [unlabeled peak area-(100-X)/X labeled peak area] / [100/X labeled peak area]. For 
example, if the incorporation percentage of 13C6-lysine and 
13C6-arginine in a protein is 
90%.  The labeled peak area only represents 90% of the peak area from the label cells. Its 
revised peak area should be 100/90 labeled peak area. The peak area originated from 
unlabeled cells should be the unlabeled peak area minus (100-90)/90 labeled peaked area.
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Chapter 4: Results
Nuclei isolation and protein extraction
      Reproducible sample preparations are crucial for comparative proteomics studies.   
We have successfully developed and evaluated methods to isolate nuclei and extract 
nuclear proteins of MCF-7 cells for subsequent 2-D gel electrophoresis. Figure 12 shows 
drug susceptible MCF-7 nuclei before and after purification. Under a light microscope 
and fluorescent microscope the purified nuclei stained with propodium iodide appeared to
be free of rough endoplasmic reticulum (ER) and other contaminants, and no difference 
could be detected between nuclei from drug susceptible and drug resistant MCF-7 cells.  
MCF-7 cells were harvested at 95% confluence. Typically, 6-8 x 106 cells were harvested 
from a 150 cm2 flask. Their total wet weight was 0.17-0.20 gram. 0.17-0.24 gram of 
nuclei was obtained from 1.0 gram of cell pellet, from which 7.5-9.0 mg of nuclear 
proteins could be acquired. 
44
Figure 12: Nuclei of control MCF-7 cells stained with propodium iodide.  a: MCF-7 
nuclei released from the cells  lysate with hypotonic buffer. b: MCF-7 nuclei after 
centrifugation with sucrose cushion.
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2-D gel electrophoresis and protein identification
      The protein samples were subjected to 2-D gel electrophoresis after desalting with a 
spin column P-6 (Biorad, Hercules, CA).  The gels were stained with Coomassie blue and 
visualized. After images were recorded digitally, the spots were excised and digested 
with trypsin. The digestion products were subjected to mass spectrometry analysis.  
Protein identifications were acquired based on peptide fingerprinting or microsequencing. 
The purity of the nuclear protein mixture was evaluated by identification of proteins on 
the gel.   Figure 13 shows an annotated 2-D gel electrophoresis map of nuclear proteins 
of control MCF-7 cells, proteins identified from which were listed in Table 1. Typically, 
proteins identified by peptide mass fingerprinting have sequence coverage above 30%. At 
least two sequence tags were acquired for each protein identified by microsequencing. 
The mascot scores all exceed the 95% confidence criteria set by the software. In most 
cases, the molecular weights and pI of each protein fit well with their position in the 2-D 
gel map. Although 160 spots were identified, only 120 different proteins were identified. 
Some proteins appeared on more than one spot in the gel. For example, spots134, 135, 
136 and 137 were of same protein hnRNP L. In rare cases, one spot contained more than 
one single protein, because 2-D gel electrophoresis can not separate proteins with both 
similar molecular weight and pI. For example, spot 72 were identified to have two 
proteins, BAF53 (PI 5.39, MW 47430) and hnRNP F (PI 5.38, MW 45985). Proteins 
having significantly smaller molecular weights than their theoretical values were judged 
as truncated.
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Figure 13: Annotated 2-D gel map of nuclear proteins from control MCF-7 cells.
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Table 1: Proteins identified from nuclear extraction of control MCF-7 cell.
Spot 
NO Protein ID PI MW Accession  NO
Subcellular 
location
1 Micrococcal Nuclease 9.8 19299 P43209
2--3 snRNP-G 8.98 8490 Q15357 N
4 Signal recognization particle 9Kd Pro 8.27 9974 P49458 N
5 P10 protein 7.3 11064 P60903 N
6 Ubiquitin 6.56 8560 P02248 N
7
U6 snRNA-associated Sm-like protein 
LSm2 6.04 10828 Q9Y333
N
8 S100 calcium-binding protein A16 6.28 11794 Q96FQ6 C,N
9 S100 calcium-binding protein A13 5.91 11464 Q99584 C,N
10 Enhancer of rudimentary homolog 5.63 12422 Q14259 N
11 snRNP-F 4.7 9776 P49458 N
12
U6 snRNA-associated Sm-like protein 
LSm7 5.1 11595 Q9UK45
N
13 60 Sacidic ribosomal protein P2 4.42 11658 P05387 N
14
U6 snRNA-associated Sm-like protein 
LSm3 4.58 11707 Q9Y4Z1
N
15 NHP-2 like protein 1 8.72 14165 P55769 N
16 Single-stranded DNA-binding protein 9.59 17249 Q04837 N
17 40S ribosomal protein S12 6.36 14728 P25398 C
18 Putative RNA-binding protein 3 8.86 17160 P98179 N
19 VAMP-associated protein 6.85 27211 O95292 MB
20 DIMI protein homolog 5.53 16775 O14834 N
21 60s ribosomal protein L23a 10.44 17684 P29316 N
22 Cyclophilin B 9.33 22785 P23284 E, N
23 NIF3L1BP1 protein 5.69 23039 Q6I9Y2
24 40S ribosomal protein S7 10.09 22113 P62081 N
25 HMG 2 7.77 24059 P26583 N
26 HMG-4L 8.45 21125 Q9UJ13 N
27 FK506-binding protein 3 9.29 25161 Q00688 N
28 PSA 2 7.12 25865 P25787 N
29-30 HMG-1 5.62 24747 P09429 N
31 HSP 27 5.98 22768 P04792 N
32 eIF4E 5.79 25082 P06730 N
33 40 S ribosomal protein SA 4.79 32833 P08861 N
34 Prohibitin 5.57 29786 P35232 C,MT, N
35 Breast carcinoma amplified sequence 2 5.48 26115 O75934 N
36 U2 small nuclear ribonucleoprotein A' 8.72 28398 P09661 N
48
37-38
Guanine nucleotide-binding protein 
beta 7.6 35055 P25388
N
39 PSA 1 6.15 29822 P25786 N
40 Nuclear protein Hcc-1 6.1 23656 P82979 N
41 Annexin IV 5.85 35729 P09525 N
42 Annexin V 4.94 35783 P08758 N
43 Splicing factor SC35 11.88 25560 Q01130 N
44 EF-1-beta 4.5 24617 P24534 C,N
45 Alpha tropomyosin 4.72 32856 P09493 CT
46 Guanine Nucleotide -binding protein 5.6 37307 P11016 N
47-48 hnRNP H3 6.37 36903 P31942 N
49 Annexin II 7.56 38677 P07355 N
50-53 hnRNP A2/B1 8.97 37464 P22622 N
54 hnRNP A1 9.26 37464 P09651 N
55-57 60 S acidic ribosomal protein p0 5.71 34252 P05388 N
58 CapZ alpha-1 5.45 32903 P52907 N
59 eIF-3 beta 2 5.38 36479 Q13347 N
60 Nucleophosmin 4.47 32746 P06748 N
61-63 Cytokeratin 19 5.04 44079 P08727 CT
64 hnRNP C 4.95 33667 P07910 N
65 Set Protein 4.12 32084 Q01105 N
66-68 Cytokeratin 8 (truncated) 4.76 53515 P05787 N
69 Actin beta 5.15 42408 P60709 N
70 Transcription factor NF-AT 45K chain 8.26 44897 gi|1082855 N
71 Elongation initiation factor 4A-1 5.32 46352 P04765 N
72/1 BAF 53 5.39 47430 O96019 N
72/2 hnRNP F 5.38 45985 P52597 N
73 PP1A 5.94 37488 P62136 C
74-75 hnRNP Do 7.62 38581 Q14103 N
76 hnRNPA3 8.74 39947 P51991 N
77 Mitotic checkpoint protein BUB 3 6.36 37131 O43684 N
78-83 hnRNP A/B 6.49 35945 Q99729 N
84 THO complex subunit 3 5.7 38747 Q96J01 N
85-86 Actin gamma 5.31 41766 P02571 CT
87 Calcium-binding transporter 5.31 45790 Q9P129 MB
88 Septin 2 6.25 41689 Q15019 CT
89 Creatine kinase 8.6 47007 P12532 MT 
49
90 Septin 7 8.85 48756 Q16181 N
91 Elongation factor 1-alpha 1 9.1 50451 P04720 C
92
Regulator of chromosome 
condensation 7.18 44941 P18754
N
93-94 Proliferation-association pro 2G4 6.13 44101 Q9UQ80 N
95 Elongaton factor 1-gamma 6.25 50429 P26641 N
96 Cleavage stimulation factor 6.12 48324 Q05048 N
97 DEK oncogene 8.69 42933 P35659 N
98 RUV-like 2 5.49 51125 Q9Y230 N
99-
100 HLA-B associated transcript-1 5.44 49416 Q13838
N
101 hnRNP H 5.89 49198 P31943 N
102 Septin 6 6.24 49685 Q14141 N
103 Glutamate dehydrogenase 1 7.66 61359 P00367 CT
104 ATP synthase alpha chain 9.16 59714 P25705 M
105 SRP 54 8.87 55668 P61011 N
106
54 kDa DNA- and RNA-binding 
Protein 9.01 54066 Q15233
N
107 ATP synthase beta chain 4.64 56525 Q14283 M
108 HAT type B subunit 4.89 48132 Q16576 N
109 CAF-1 subunit 4.74 47911 Q09028 N
110 Splicing factor 3A subunit 3 5.27 58812 Q12874 N
111 hnRNP K (truncated) 5.39 51230 Q07244 N
112-
115 hnRNP K 5.39 51230 Q07244
N
116 Copine III 5.6 60947 O75131 N
117 T-complex protein 1, beta 6.01 57452 P78371 N
118 Nuclear matrix pro 200 6.14 55603 Q9UMS4 N
119 RuvB-like 1 6.02 50538 Q9Y265 N
120 Aspartyl-tRNA synthetase 6.11 57100 P14868 C, N
121 Glutamate dehydrogenase 1 7.66 61359 P00367 M
122 U4/U6 sn RNP 7.05 59097 O43172 N
123
Phenylanyl-tRNA synthetase alpha 
chain 7.46 57396 Q9Y285
C, N
124 Probable RNA-dependent helicase p68 9.06 69105 P17844 N
125 T-complex protein 1, alpha 5.8 60306 P17987 C
126 Nucleolin (76K) 4.41 76224 P19338 N
127 Heat shock cognate 71 kDa 5.37 71082 P11142 C,N
128 HSP 70-1 5.48 70294 P08107 M
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129 Stress-70 protein 5.87 73635 P38646 M
130 Annexin VI 5.42 75695 P08133 N
131 Delta coat protein 5.89 57174 P48444 MB
132 Stress-induced-phosphoprotein 1 6.4 63227 P31938 C, N
133
Phenylanyl-tRNA synthetase beta 
chain 6.4 66088 Q9NSD9
C, N
134-
137 hnRNP L 6.65 60719 P14866
N
138-
139 hnRNP Q 8.68 69590 O60506
N
140-
141
ATP-depedent DNA helicase II, 80kDa 
subunit 5.55 83091 P13010
N
142 liscening factor 6.08 81884 P33993 N
143-
144
ATP-depedent DNA helicase II, 70kDa 
subunit 6.23 69953 P12956
N
145 ATP-dependent helicase DDX1 6.81 82380 Q92499 N
146-
147 EF-2 6.42 96116 P13639
C
148-
149 C1-THF synthase 6.94 101364 P11586
C
150 Splicing factor PQ 9.45 762116 P23246 N
151 PARP-1 8.99 113680 P09874 N
152-
153 Structure maintaince of chromosome 3 6.77 141454 Q9UQE7
N
154 Structure maintaince of chromosome 1 7.51 143144 Q14683 N
155-
156
Bifunctional aminoacyl-tRNA 
synthetase 7.77 161923 P07814
N
157-
158 TER AtPase 5.14 89950 P55072
N
159 Nucleolin (100K) 4.41 76224 P19388 N
160 hnRNP U 5.76 90423 Q00839 N
N – Nuclear      C – Cytoplasmic     MT – Mitochondria
E – Endoplasmic reticulum   CT-cytoskeleton    MB-membrane
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Evaluation of 13C6-arginine and 
13C6-lysine metabolic labeling
      The nuclear protein expression profile of control MCF-7 cells with isotope 13C6-
arginine and 13C6-lysine media was compared with that of control MCF-7 cells cultured 
in regular media. The MCF-7 cells were cultured in growth media with 13C6- arginine and 
13C6-lysine. After 5 passages, the cells were harvested and nuclear proteins were 
extracted. The protein sample was subjected to 2-D gel electrophoresis. The gel images 
were taken and compared with those from control MCF-7 cells cultured in regular media. 
The spots were excised and digested with trypsin. The subsequent peptides were analyzed 
with mass spectrometers. The gel image comparison showed that the protein expression 
profile of control MCF-7 cells with isotope labeling represented that of control MCF-7 
cells cultured in regular media. Figure 14 shows a 2-D gel map of nuclear proteins of 
control MCF-7 cells in regular media. Figure 15 shows a 2-D gel map of nuclear proteins 
of control MCF-7 cells cultured in 13C6- arginine and 
13C6-lysine media. In addition, mass 
spectrometry analysis indicated that 13C6- arginine and 
13C6-lysine were incorporated into 
the proteins at about 90%. Figure 16 shows incorporation of 13C6- arginine and 
13C6-
lysine in nucleophosmin.
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Figure 14: 2-D gel map of nuclear proteins from control MCF-7 cells in regular media.
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Figure 15: 2-D gel map of nuclear proteins from control MCF-7 cells in 13C6- arginine 
and 13C6-lysine media.
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                       Incorporation Percentage: 89 Incorporation Percentage: 90
Figure 16: Evaluation of metabolic incorporation of isotope 13C6 in nucleophosmin.
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Nuclear protein expression profile of MCF-7/VP cells
      The expression profile of Vp-16 resistant MCF-7 cells was compared with that of 
control MCF-7 cells with both densitometric comparison and metabolic labeling 
methods. Figure 17 shows a 2-D gel map of nuclear proteins from VP-16 resistant MCF-
7 cells.  Figure 18 shows 2-D gel map of nuclear proteins from VP-16 resistant MCF-7 
cells and labeled control MCF-7 cells mixture. Figure 19 shows the results of 
densitomeric comparison of a pair of 2-D gel arrays of nuclear proteins from control and 
VP-16 resistant MCF-7 cells made using Compugen software.  Of the 120 proteins 
identified, abundances of 9 proteins were found significantly more or less abundant using 
2-fold as the threshold. Those are circled in Figure 19. Nucleolin, HMG 1, 40s ribosomal 
protein SA and cyclophilin B are more abundant. Cytokeratin 8, cytokeratin 19, septin 2, 
PARP-1 and alpha tropomyosin are less abundant. Figure 20 shows an example of gel 
arrays and mass spectra of a protein whose abundance levels are the same in the two cell 
lines. The protein was identified as nuclephosmin.  It was subsequently used as a control 
for cell mixing. Figure 21 shows gel arrays and mass spectra of nucleolin, which reveals 
that it was more abundant in VP-16 resistant MCF-7 cells. Figure 22 shows gel arrays 
and mass spectra of septin 2, which was less abundant in VP-16 resistant MCF-7 cells. 
Table 2 provides the results of protein relative abundance in VP-16 resistant cells with 
both methods.
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Figure 17: 2-D gel map of nuclear proteins of MCF-7/VP cells.
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Figure 18: 2-D gel map of nuclear proteins of MCF-7/VP cells and labeled control MCF-
7 cells.
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Figure 19: Densitometric comparison of 2-D gels of nuclear proteins: control vs. MCF-
7/VP cells.
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                            Control                                             VP-16
A: Enlarged images showing nucleophosmin with equal abundance
B: Metabolic labeling showing nucleophosmin with equal abundance
Figure 20: Nucleophosmin has no change in abundance in MCF-7/VP cells.
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A: Enlarged images showing nucleolin with higherl abundance
B: Metabolic labeling showing nucleolin with higher abundance
Figure 21: Nucleolin has a higher abundance in MCF-7/VP cells.
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                       Control                                                    VP-16
A: Enlarged images showing septin 2 with lower abundance
B: Metabolic labeling showing septin 2 with lower abundance
Figure 22: Septin 2 has a lower abundance in MCF-7/VP cells.
Septin 2 Septin 2
MALDI-TOF spectra of septin 2 in Isotope mixture Peptide: [YLHDESGLNR+H]+
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Table 2: Relative abundance of nuclear proteins from MCF-7/VP cells.
Protein ID
 Ratio by comparative 
densitometry (VP-
16/Control)
 Ratio by stable isotope 
labeling (VP-
16/Control)
Nucleolin (76K) 2.78 ±0.23 3.15 ±0.26
40 S ribosomal protein SA 1.72 ±0.28 2.25 ± 0.28
Cyclophilin B 2.04 ±0.14 2.12 ±0.11
HMG-1 2.1 ±0.18 2.1 ± 0.18
Nucleolin (100K) 2.08 ±0.39 1.87±0.14
NHP-2 like protein 1 1.62 ±0.20 1.82±0.23
PP1A 1.88 ±0.19 1.79±0.22
HAT type B subunit 1.94 ±.016 1.71 ± 0.36
Guanine nucleotide-binding protein 
beta 1.05 ±0.12 1.60 ± 0.28
Structure maintaince of 
chromosome 1 1.3 ±0.13 1.56 ± 0.24
HMG-4L 1.44 ±0.16 1.56±0.08
Splicing factor 3A subunit 3 0.94 ±0.21 1.55 ± 0.28
snRNP-G 1.41 ±0.16 1.55 ± 0.40
Enhancer of rudimentaryhomolog 1.12±0.32 1.52±0.23
Breast carcinoma amplified 
sequence 2 1.38 ±0.23 1.51 ± 0.24
40S ribosomal protein S12 0.91 ±0.12 1.51±0.31
Single-stranded DNA-binding 
protein 1.04 ±0.15 1.5 ± 0.31
40S ribosomal protein S7 1.48 ±0.4 1.48 ± 0.26
THO complex subunit 3 1.23 ±0.18 1.44±0.21
ATP synthase alpha chain 1.06 ±0.02 1.44 ± 0.26
DEK oncogene 1.15 ±0.06 1.43±0.23
Annexin IV 1.14 ±0.15 1.41±0.15
Nuclear matrix pro 200 0.91 ±0.07 1.36 ± 0.31
HLA-B associated transcript-1 1.31 ±0.12 1.35 ± 0.25
NIF3L1BP1 protein 1.18 ±0.18 1.34 ± 0.23
ATP-dependent helicase DDX1 1.2±0.15 1.34 ± 0.10
U2 small nuclear ribonucleoprotein 
A' 0.91 ±0.10 1.33 ± 0.23
S100 calcium-binding protein A13 0.95 ±0.09 1.33 ± 0.31
U6 snRNA-associated Sm-like 
protein LSm7 1.1 ±0.09 1.32±0.11
hnRNP A2/B1 0.88 ±0.09 1.30 ± 0.24
Cleavage stimulation factor 0.8 ±0.09 1.30 ± 0.25
63
hnRNP Do 1.05 ±0.12 1.29±0.23
HSP 27 1.35 ±0.21 1.26 ± 0.12
Structure maintaince of 
chromosome 3 1.2 ±0.24 1.26 ± 0.09
Splicing factor PQ 0.78 ±0.16 1.26 ± 0.58
Set Protein 2.84 ±0.22 1.25±0.19
hnRNP Q 1.21±0.09 1.25±0.12
60 Sacidic ribosomal protein P2 0.7 ±0.09 1.25 ± 0.24
Elongation initiation factor 4A-1 1.17 ±0.13 1.24 ± 0.36
Prohibitin 1.72 ±0.12 1.24 ± 0.12
Stress-70 protein 1.18 ±0.15 1.23±0.13
Elongaton factor 1-gamma 1.04 ±0.17 1.23 ± 0.36
EF-2 1.3 ±0.21 1.2±0.15
BAF 53 1.17 ±0.12 1.20 ± 0.36
RuvB-like 1 0.63 ±0.06 1.17 ± 0.10
Ubiquitin 0.79 ±0.11 1.14 ± 0.19
hnRNP K (truncated) 0.68 ±0.07 1.14± 0..24
hnRNP L 0.89 ±0.09 1.13 ± 0.19
ATP-depedent DNA helicase II, 
80kDa subunit 1.08 ±0.09 1.13±0.14
Stress-induced-phosphoprotein 1 0.98 ±0.06 1.09±0.12
SRP 54 1.0 ±0.08 1.09±0.05
S100 calcium-binding protein A16 0.61 ±0.19 1.09 ± 0.09
hnRNPA3 1.29 ±0.09 1.08 ± 0.36
Atp-depedent DNA helicase II, 
70kDa subunit 0.99±0.12 1.08 ± 0.10
hnRNP K 1.1 ±0.06 1.07 ± 0.12
EF-1-beta 1.02±0.08 1.06±0.12
Annexin II 0.79±0.10 1.06 ± 0.24
Regulator of chromosome 
condensation 0.97 ±0.09 1.05±0.06
Elongation factor 1-alpha 1 1.66 ±0.15 1.05 ± 0.21
Aspartyl-tRNA synthetase 0.98 ±0.07 1.05 ± 0.05
Annexin V 0.21 ±0.04 1.05±0.21
60 S acidic ribosomal protein p0 0.79 ±0.12 1.02±0.03
RUV-like 2 1.56 ±0.21 1.00 ± 0.21
Proliferation-association pro 2G4 1.28 ±0.11 1.00 ± 0.16
Mitotic checkpoint protein BUB 3 1.22 ±0.13 1.00 ± 0.11
hnRNP A1 0.96±0.13 1.00 ±  0.22
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ATP synthase beta chain 1.06 ±0.12 1.00 ± 0.16
Transcription factor NF-AT 45K 
chain 1.1 ±0.13 0.99 ± 0.30
Phenylanyl-tRNA synthetase beta 
chain 1.13±.015 0.99±0.12
CAF-1 subunit 0.88 ±0.12 0.98 ± 0.11
Signal recognization particle 9Kd 
Pro 0.87 ±0.09 0.97 ± 0.30
Heat shock cognate 71 kDa 0.57 ±0.10 0.96 ± 0.05
eIF-3 beta 2 0.85 ±0.13 0.96±0.30
Calcium-binding transporter 1.0 ±0.06 0.96±0.05
Nucleophosmin 0.96 ±0.12 0.95 ±  0.04
Copine III 1.39 ±0.16 0.95 ±  0.26
hnRNP A/B 0.98 ±0.16 0.94 ± 0.26
eIF4E 1.92 ±0.21 0.93 ± 0.09
Guanine Nucleotide -binding 
protein 0.81 ±0.20 0.87±0.05
Creatine kinase 1.68±0.26 0.86 ± 0.20
Actin gamma 1.32 ±0.16 0.85 ± 0.31
Splicing factor SC35 0.87 ±0.12 0.83 ± 0.20
Glutamate dehydrogenase 1 1.03 ±0.09 0.81 ± 0.12
U6 snRNA-associated Sm-like 
protein LSm2 0.69 ±0.10 0.77 ± 0.10
T-complex protein 1, beta 0.72 ±0.10 0.77 ± 0.23
snRNP-F 1.1 ±0.07 0.76±0.10
C1-THF synthase 0.64 ±0.13 0.74 ± 0.13
54 kDa DNA- and RNA-binding 
Protein 1.43 ±0.13 0.74 ± 0.18
HMG 2 0.61±0.05 0.72±0.12
Actin beta 0.79 ±0.14 0.69 ± 0.10
Delta coat protein 0.31 ±0.06 0.68 ± 0.09
HSP 70-1 0.47 ±0.12 0.67±0.07
Septin 7 0.81 ±0.11 0.64 ±  0.13
Annexin VI 0.53 ±0.07 0.62±0.07
Cytokeratin 8 (truncated) 0.47 ±0.10 0.45 ± 0.15
hnRNP H3 0.65 ±0.11 0.44 ± 0.10
Cytokeratin 19 0.58±0.09 0.43 ± 0.06
PARP-1 0.62 ±0.10 0.4 ±0.06
Septin 2 0.44 ±0.04 0.26±0.04
Alpha tropomyosin unamtched 0.11±0.03
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Nuclear protein expression profile of MCF-7/MX cells
      The nuclear proteins from mitoxantrone resistant MCF-7 cells were analyzed by both 
densitometric comparison and metabolic labeling methods. However, a limited number of 
spots were analyzed by the metabolic labeling method guided by the results of 
densitometric comparisons. Prohibitin, 78K glucose-regulated protein (GRP78), HMG-1, 
40S ribosomal protein SA, and nucleolin were found to be significantly more abundant
(more than 2 fold). Cytokeratin19, cytokeratin 8, septin 2, PARP-1 and alpha 
tropomyosin were found to be less abundant. Figure 23 shows a 2-D gel map of nuclear 
proteins from MCF-7/MX cells. Figure 24 shows a 2-D gel map of mixture of nuclear 
proteins from MCF-7/MX cells and isotope labeled control MCF-7 cells.  Figure 25
shows the results of the densitometric comparison of a pair of 2-D gel arrays of nuclear 
proteins from control and MCF-7/MX cells made using Compugen software. Identified 
proteins with significant changes in abundance are circled. GRP78 was not shown in the 
annotated 2-D gel map of nuclear proteins from control MCF-7 cells because it was not 
checked initially. Retrospective inspections indicated that there was a weak spot on its 
position in 2-D gel of control sample. Table 3 provides results for proteins analyzed with 
both methods.
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Figure 23: 2-D gel map of nuclear proteins from MCF-7/MX cells.
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Figure 24: 2-D gel map of nuclear proteins from MCF-7/MX cells and isotope labeled 
control MCF-7 cell mixture.
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Figure 25: Densitometric comparison of 2-D gels of nuclear proteins: control vs. MCF-
7/MX cells.
More abundant Less abundant Unmatched
3 10 NL
100 K
60 K
35 K
20 K
10 K
GRP78
69
Table 3: Relative abundance of nuclear proteins from MCF-7/MX cells.
Protein ID  Ratio by comparative 
densitometry (MTX/Control)
 Ratio by stable 
isotope labeling 
(MTX/Control)
78kGlucose-regulated protein 5.53±0.69 4.91±0.46 
Prohibitin 2.81±0.31 3.69±0.33
HMG-1 1.52±0.16 2.56±0.18
40 S ribosomal protein SA 1.74±0.19 2.35±0.15
Cyclophilin B 1.66±0.45 2.22±0.16
Nucleolin(70K) 1.98±0.24 2.18±0.16
hnRNP Do 1.60±0.17 1.82±0.13
Nuclear matrix protein 200 1.47±0.40 1.75±0.20
Cleavage stimulation factor 1.49±0.26 1.46±0.14
Mitotic checkpoint protein BUB 3 1.68±0.32 1.42±0.11
Proliferation-association pro 2G4 1.58±0.14 1.42±0.13
Stress-70 protein 1.42±0.16 1.34±0.13
HSP 27 0.82±0.17 1.31±0.23
Elongaton factor 1-gamma 0.85±0.23 1.31±0.11
Cleavage stimulation factor 1.89±0.12 1.26±0.21
Atp-depedent DNA helicase II, 70kDa 
subunit 1.21±0.21 1.25±0.15
Enhancer of rudimentary homolog 1.02±0.11 1.2±0.14
hnRNPA3 1.33±0.17 1.13±0.26
hnRNP L 1.11±0.19 1.09±0.12
Nucleophosmin 0.88±0.18 1.02±0.17
Set Protein 1.55±0.22 0.99±0.22
Septin 7 1.2±0.19 0.97±0.16
Guanine nucleotide-binding protein 
beta 1.0±0.16 0.95±0.11
Heat shock cognate 71 kDa 0.68±0.23 0.92±0.10
Breast carcinoma amplified sequence 2 1.23±0.31 0.91±0.12
CAF-1 subunit 0.76±0.24 0.81±0.15
Actin beta 0.69±0.10 0.66±0.20
Cytokeratin 19 0.58±0.14 0.53±0.09
Cytokeratin 8 (truncated) 0.43±0.06 0.49±0.05
PARP-1 0.30±0.13 0.46±0.06
EF-1-beta 0.28±0.09 0.36±0.06
Septin 2 0.22±0.03 0.11±0.03
Alpha tropomyosin unmatched 0.10±0.02
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Nuclear protein expression profile of MCF-7/AdrVp cells
      The nuclear proteins from MCF-7/AdrVp were also analyzed by both densitometric 
comparison and isotope labeling methods. Mitotic checkpoint protein BUB 3 and 
cyclophilin B were found more abundant. Septin2, septin7, cytokeratin19, cytokeratin 8 
and alpha tropomyosin were found to be less abundant. Figure 26 shows a 2-D gel map of 
nuclear proteins from MCF-7/AdrVp cells. Figure 27 shows a 2-D gel map of nuclear 
proteins from control isotope labeled MCF-7 cells and MCF-7/Adrvp cells. Figure 28
shows the results of densitometric comparison of a pair of 2-D gel arrays of nuclear 
proteins from control and MCF-7/AdrVp cells made using Compugen software. 
Identified proteins with significant abundance change are circled. Table 4 provides 
relative abundances of some nuclear proteins in MCF-7/AdrVp cells.
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Figure 26: 2-D gel map of nuclear proteins from MCF-7/AdrVp cells.
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Figure 27: 2-D gel map of nuclear proteins from MCF-7/AdrVp cells and isotope labeled 
control MCF-7 cell mixture.
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Figure 28: Densitometric comparison of 2-D gels of nuclear proteins: control vs. MCF-
7/AdrVp cells.
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Table 4: Relative abundance of nuclear proteins from MCF-7/AdrVp cells.
Protein ID
 Ratio by comparative 
densitometry 
(AdrVp/Control)
 Ratio by stable 
isotope labeling 
(AdrVp/Control)
Cyclophilin B 1.92±0.22 2.32±0.16
Mitotic checkpoint protein BUB 3 2.01±0.19 2.23±0.13
hnRNP K (truncated) 1.75±0.21 1.56±0.35
HMG 2 1.66±0.24 1.66±0.34
Creatine kinase 1.65±0.27 0.82±0.16
Regulator of chromosome condensation 0.84±0.14 1.42±0.23
RuvB-like 1 1.35±0.19 1.42±0.21
ATP synthase beta chain 1.53±0.16 1.35±0.16
40 S ribosomal protein SA 1.33±0.25 1.34±0.20
snRNP-G 1.23±0.17 1.32±0.19
HMG-1 1.68±0.30 1.28±0.13
hnRNP A1 0.64±0.16 1.25±0.24
Elongation initiation factor 4A-1 1.21±0.14 1.25±0.14
Nuclear matrix pro 200 1.12±0.14 1.25±0.16
EF-2 1.43±0.27 1.25±0.16
HLA-B associated transcript-1 1.04± 0.19 1.24±0.16
Splicing factor PQ 0.92±0.09 1.21±0.14
ATP-depedent DNA helicase II, 70kDa subunit 1.01±0.19 1.11±0.17
HSP 27 1.27±0.16 1.09±0.25
C1-THF synthase 1.03±0.21 1.06±0.10
Enhancer of rudimentaryhomolog 1.31±0.16 1.02±0.13
Breast carcinoma amplified sequence 2 0.83±0.24 1.02±0.19
ATP-dependent helicase DDX1 0.87±0.21 1.02±0.12
hnRNP A/B 0.89±0.16 0.99±0.12
Splicing factor 3A subunit 3 0.66 ±0.14 0.98±0.07
eIF4E 1.03±0.19 0.96±0.14
BAF 53 1.31± 0.16 0.96±0.10
CAF-1 subunit 1.38±0.22 0.95±0.12
Prohibitin 0.77±0.13 0.87±0.14
40S ribosomal protein S12 0.66±0.11 0.86±0.09
54 kDa DNA- and RNA-binding Protein 0.84 ±0.16 0.86±0.21
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S100 calcium-binding protein A16 0.91±0.17 0.85±0.14
hnRNP L 1.03±0.16 0.83±0.09
40S ribosomal protein S7 0.91±0.23 0.82±0.08
Annexin II 0.59±0.06 0.82±0.09
hnRNP A2/B1 0.86±0.18 0.82±0.10
Elongation factor 1-alpha 1 1.14±0.22 0.82±0.20
Cleavage stimulation factor 1.23±0.16 0.82±0.14
RUV-like 2 0.93 ±0.21 0.82±0.14
Nucleolin(76K) 0.69±0.16 0.81±0.16
Nucleolin(100K) 0.79 ±0.21 0.79±0.11
S100 calcium-binding protein A13 0.69±0.24 0.76±0.14
Aspartyl-tRNA synthetase 0.68±0.22 0.76±0.12
Nucleophosmin 1.1±0.21 0.74±0.15
U6 snRNA-associated Sm-like protein LSm7 1.21±0.13 0.7±0.09
P10 protein 0.66±0.09 0.69±0.09
PARP-1 0.93±0.29 0.65±0.10
Actin beta 0.68±0.15 0.65±0.09
Proliferation-association pro 2G4 0.84±0.26 0.58±0.07
Glutamate dehydrogenase 1 0.65±0.14 0.58±0.06
HMG-4L 0.75±0.16 0.57±0.06
Septin 2 0.65±0.21 0.49±0.04
Septin 7 0.36±0.10 0.32±0.07
Cytokeratin 19 0.33±0.10 0.25±0.03
Cytokeratin 8 (truncated) 0.37±0.15 0.25±0.04
EF-1-beta 0.19±0.05 0.14±0.03
Alpha tropomyosin unmatched 0.09±0.01
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Nuclear protein expression profile of MCF-7/Adr cells
      The nuclear proteins from MCF-7/Adr were analyzed only with densitometric 
comparison method. The expression profile of nuclear proteins from MCF-7/Adr was 
found to be dramatically different from that of control MCF-7 cells as expected. Figure 
29 shows a 2-D gel map of nuclear proteins from MCF-7/Adr cells. Figure 30 shows the 
results of densitometric comparison of a pair of 2-D gel arrays of nuclear proteins from 
control and MCF-7/AdrVp cells made using Compugen software. About 1/5 of the 
visible proteins that are expressed in control MCF-7 cells are not detected in MCF-7/Adr 
cells. There are also spots that are not detected from control MCF-7 cells detected from 
mcf-7/Adr. These spots are marked as “unmatched”.
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Figure 29: 2-D gel map of nuclear proteins from MCF-7/Adr cells.
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Figure 30: Densitometric comparison of 2-D gels of nuclear proteins: control vs. MCF-
7/Adr cells.
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Table 5: Nuclear proteins having abundance changes in MCF-7/Adr cells.
um - Unmatched
Protein ID
Ratio by comparative 
densitometry (Adr/Control)
Annexin IV 2.76±0.54
Annexin V 2.62±0.41
FK506-binding protein 3 3.12±0.44
hnRNP H3 3.65±0.51
P10 protein 2.64±0.34
PARP-1 3.46±0.61
40S ribosomal protein S12 um
60 Sacidic ribosomal protein P2 um
ATP synthase beta chain um
Breast carcinoma amplified sequence 2 um
CAF-1 subunit um
Cytokeratin 19 um
Cytokeratin 8 (trunk) um
DEK oncogene um
Enhancer of rudimentary homolog um
HAT type B subunit um
hnRNP C um
hnRNP K um
S100 calcium-binding protein A13 um
Septin 2 um
Septin 6 um
Set Protein um
snRNP-F um
U6 snRNA-associated Sm-like protein 
LSm3 um
U6 snRNA-associated Sm-like protein 
LSm7 um
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Chapter 5:  Discussion
2-D gel electrophoresis and protein identification
      We have developed a method to isolate nuclei and extract soluble nuclear proteins 
from MCF-7 cells. The nuclear proteins were subjected to 2-D gel electrophoresis. Many 
of the protein spots were identified by peptide mass fingerprinting and microsequencing. 
More than 90% of these proteins are classically cataloged as nuclear proteins or proteins 
that may present in the nucleus. Some of the non-nuclear proteins have also been found in 
other researchers’ nuclear protein preparation (119-121). For example, ATP synthase beta 
chain (spot 104) is classified as a mitochondrial protein, it has also been found in directed 
proteomics analysis of human nucleolus by Anderson et al (2002). This may indicate that 
this protein is closely associated with the nucleus. It needs to be pointed out that further 
purification often causes low recovery of samples in organellar proteomics (122-123). A 
balance must be found between sample purity and recovery. Our samples contained 
highly enriched soluble nuclear proteins. A 2-D gel map of soluble nuclear proteins has 
been obtained in this research. It can be used for further study of soluble nuclear proteins 
in MCF-7 cells.
Densitometry vs. isotope labeling
      We used densitometric comparisons and isotope labeling methods to analyze 
differentially abundant soluble nuclear proteins in drug resistant and susceptible MCF-7 
cells. The results by the two methods are consistent (Table 2, 3, 4) in most cases. Two-
dimensional gel electrophoresis remains the technique of choice for proteomics studies. It 
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can separate and provide a global view of many proteins in a gel. After the gel images are 
digitized, they can be compared conveniently with a very low cost. For densitometric 
comparison, the reproducibility of the sample preparations is crucial. The poor quality of 
isoelectric focusing of extremely basic proteins poses a special problem for determining 
relative abundances. For a protein with extremely high abundance, computer software 
sometimes can not properly recognize its spot as a single protein. This may also cause 
comparison errors.  The densitometric comparison also can not deal well with a spot 
containing more than one protein. Isotope labeling methods can minimize process 
variations. The relative abundances of several proteins in one spot can be differentiated. 
However, the high cost of isotopes is a disadvantage. It is only applicable to cultured 
cells.
Biological implications of abundance changes
      We have identified about a dozen proteins whose abundance is changed in each of the 
resistant MCF-7 cell lines resistant to etoposide, mitoxantrone, and adriamycin in the 
presence of verapamil. Table 6 summarizes the abundance changes in the three drug 
resistant cell lines. Those proteins may play important roles in conferring drug resistance 
in MCF-7 cancer cells. Their biological functions and potential implications are discussed 
in the following paragraphs. In contrast, expression profile of soluble nuclear proteins 
from MCF-7/Adr cells is dramatically different from that of control MCF-7 cells. About 
20 proteins identified in control MCF-7 cells are not detected in MCF-7/Adr cells 
(unmatched spots). Profiling of cytosolic proteins in our lab has also led to the suggestion 
that the cell line has an uncertain identity (69). Thus the results from this cell line are 
excluded from further consideration. 
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Table 6: Summary of abundance changes in three drug resistant MCF-7cell lines*.
                                        Cell line
Protein MCF-7/VP MCF-7/MX MCF-7/AdrVp
78 k glucose -regulated protein nd 4.91±0.46 1.09±0.16
prohibitin 1.24±0.12 3.69±0.33 0.95±0.11
HMG-1 2.1±0.18 2.56±0.18 1.28±0.13
40S ribosomal protein SA 2.25±0.28 2.35±0.18 1.34±0.14
Cyclophilin B 2.12±0.11 2.22±0.16 2.32±0.16
Nucleolin(76K) 3.15±0.26 2.18±0.16 0.81±0.16
Nucleolin (100K) 1.87±0.14 1.58±0.18 0.79±0.11
Mitotic checkpoint protein BUB 3 1.00±0.11 1.42±0.11 2.23±0.13
Cytokeratin 19 0.45±0.15 0.53±0.09 0.25±0.03
Cytokeratin 8 0.43±0.06 0.49±0.05 0.25±0.04
Septin 2 0.26±0.04 0.11±0.03 0.49±0.04
EF-1-beta  1.06±0.12 0.36±0.06 0.14±0.03
Alpha tropomyosin  0.11±0.03 0.10±0.02 0.09±0.01
Septin 7 0.64±0.11 0.97±0.11 0.32±0.07
PARP-1 0.40±0.06 0.46±0.06 0.65±0.10
                                 Higher abundance             Lower abundance   
*Based on metabolic labeling     nd: not determined
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Lower abundance of poly [ADP-ribose] polymerase (PARP)-1 
      PARP-1(spot 151) was found to be significantly less abundant in MCF-7/VP, MCF-
7/MX than in control MCF-7 cells, with ratios of 0.40±0.06 and 0.46±0.06, respectively. 
It also has a lower abundance in MCF-7/AdrVp (0.65±0.10), but does not meet the 2-fold 
threshold that we set as a significant change.
PARP-1 is a 114 kDa nuclear zinc-finger enzyme, catalyzing the attachment of ADP 
ribose units to target proteins. It targets proteins directly involved in DNA metabolism 
and regulation of chromatin structure, such as topoisomerases, DNA ligases, or DNA 
polymerases (124). PARP-1 activity increases substantially in response to genotoxic 
stress. It has been found to be involved in DNA repair (125-127). PARP-1 acts as a 
sensor of DNA damage, and forms a functional complex with XRCC1 protein in base 
excision repair (126). It also provides ATP for the DNA ligation step (127).
 It has also been shown that PARP-1 is involved in cell death (129-134). PARP-1 
seems to signal a p53-independent cell death pathway (130). Chirugi and Yu et al (2002)
have proposed a PARP-1-dependent signaling pathway in apoptosis (131-132). This 
pathway starts with activation of PARP-1 after genotoxic stimuli. PARP-1 activation 
leads to massive synthesis of poly [ADP-ribose], which subsequently causes NAD+
depletion. Poly [ADP-ribose] formation and NAD+ depletion trigger mitochondrial 
depolarization and release of a mitochondrial apoptosis-inducing factor (AIF) that 
promotes programmed cell death through a caspase-independent pathway. It is 
controversial whether this is necrosis or apoptosis (132). However, the result of the 
process is cell death. Recent studies show DNA-damaging agents selectively induce 
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tumor death through this pathway independent of p-53 or Bcl-2 family proteins (133-
134). In addition, independent research has shown that PARP-1 is up-regulated at the 
early stage of apoptosis induced by UV irradiation (135). Mouse cells lacking PARP-1 
has been observed to have increased resistance to anticancer therapy (136). 
Overproduction of PARP-1 has been implicated in the molecular pathway leading to cell 
death by energy depletion following stress (137). In the present research, lower 
abundance of PARP-1 is closely correlated with drug resistance in MCF-7 cells. It is 
potentially responsible for drug resistance conferred by MCF-7 cells by repressing cell 
death through this signaling pathway. It is likely that the low level of PARP-1 can not 
fulfill the requirement of PARP-1 activation at the first step.
Lower abundance of cytoskeletal proteins
       Cytoskeletal proteins, including alpha tropomyosin (spot 45), cytokeratin 19 (spot 
61-63), cytokeratin 8 (spot 66-68) and septin 2 (spot 88), were found to be less abundant 
in MCF-7/VP, MCF-7/MX, and MCF-7/AdrVp cells than in control MCF-7 cells. Septin 
7 was found to be less abundant in MCF-7/AdrVp only. Cytoskeletal functions range 
from cellular architecture to signal transduction and apoptosis (138-141). Cytokeratins 
are common contaminants from human fingers, in our experiments, the finding of isotope 
labeled cytokeratins ruled out the possibility of contamination. Several papers have 
linked differential expression of those proteins to drug resistance (142-144). Cytokeratins 
and alpha tropomyosin have been reported to be up- and down-regulated in breast cancer 
cells than normal breast cells (145). Tropomyosin was found to be down-regulated in 
drug resistant SNU 638 gastric cancer cells compared to their parental cells (144).  
However, the nucleus is not the major subcellular location of the proteins. The results 
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from this research may indirectly reflect the abundance of the proteins in the whole cells. 
Analysis of whole cell lysate can give more conclusive results. 
Higher abundance of nucleolin
Nucleolin is a multifunctional nuclear protein with high abundance. Two forms of 
nucleolin, differing in the amino acid composition with N-terminal domain, 100 K Da 
and 76K Da (Spot126, spot 159), were found in 2-D gel map from MCF-7 Cells. 
Nucleolin of 76K Da was found to have significantly higher abundance in MCF-7/VP 
and MCF-7/MX cells, accompanied by moderately higher abundance of 100 KDa 
nucleolin.
      Nucleolin is a highly abundant nuclear protein. It can interact with DNA or RNA or 
proteins. Nucleolin exhibits intrinsic self-cleaving, DNA helicase, RNA helicase and 
DNA-dependent ATPase activities (146-148). Nucleolin also acts as a sequence-specific 
RNA binding protein, an autoantigen (149), and as the component of a B cell specific 
transcription factor (150). Its activities are regulated by proteolysis, methylation, ADP-
ribosylation, and phosphorylation (147). It has been implicated to be involved directly or 
indirectly in apoptosis, chromatin structure, DNA replication, recombination, repair, 
ribosome biogenesis and maturation, nucleolar-cytoplasmic transport, cytokinesis, 
embryogenesis, nucleogenesis, cell proliferation and growth, and transcriptional 
repression (135,149-156). It is fundamental to the survival and proliferation of cells. The 
regulation of all these functions of a single protein is a challenging puzzle. As its 
contribution to drug resistance in cancer cells, we focus on its functions in apoptosis and 
DNA repair.
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      Apoptosis in U937 leukemia cells is accompanied by lower level and localization 
alteration of nucleolin within the nucleus (135). It is suggested that apoptosis in HL-60 
cells induced by taxol and okadaic acid treatment is through a process that involves 
down-regulation of nucleolin and destabilization of bcl-2 mRNA. Nucleolin was 
identified as an AU-rich element binding protein involved in stabilization of mRNA of 
bcl-2, a known apoptosis inhibitor (152). Nucleolin has also been identified as a 
genotoxic stress-responsive protein. Nucleolin expression levels were found to be 
increased in Chinese hamster ovary (CHO) cells after UV or ionizing radiation exposure
(149). It has been reported to form a complex with replication protein A after cell stress 
to prevent initiation of DNA replication and mobilize DNA repair (155). The C-terminal 
domain of nucleolin accelerates nucleic acid annealing.  Its ability to promote 
homologous DNA pairing in vitro may also indicate it has similar function in vivo (151). 
It has been demonstrated that nucleolin interacts with topoisomerase I. It is not known if 
nucleolin interacts with topoisomerase II, which is the target of the VP-16 and 
mitoxantrone (156-157). Taken together, the up-regulation of nucleolin may inhibit 
apoptosis and enhance DNA repair in drug resistant MCF-7 cells.
Higher abundance of high mobility group protein-1(HMG-1)
      HMG-1(also called HMGB-1) (spot29, 30) was found more abundant in MCF-7/VP
and MCF-7/MX cells. HMG1 is a non-histone chromosomal protein encoded by HMGB1 
gene (158). It binds DNA without sequence specificity, but has a high affinity for bent or 
distorted DNA, and bends linear DNA. It seems to play an architectural role in the 
assembly of nuclear protein complex in a variety of biological processes, such as DNA 
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replication, transcription, recombination, and repair, but the mechanism of these 
processes is not clear(159). It has been suggested that HMGB1 is involved in chromatin 
structural modulation in global nuclear events through its interaction with a multiprotein 
complex in mammalian cells (160). It was found to inhibit cell death in yeast and 
mammalian cells and to be abundantly expressed in human breast carcinoma (161). The 
higher abundance of HMG1 may contribute to drug resistance to VP-16 and mitoxantrone 
by enhancing DNA repair, or modulating chromatin structure, thus interfering with drug 
action.
Higher abundance of 40S ribosomal protein SA
       40S ribosomal protein SA (spot33) was found to have a higher abundance in MCF-
7/VP and MCF-7/MX cells. It is a 33k Da protein which has been reported to be 
associated with drug resistance (162-165). It is also called multidrug resistance-
associated protein MGr1-Ag (162). It was originally thought to be a laminin receptor
(163). It was found to be essential for 40S ribosomal unit maturation (166). It was 
suggested to play a role in the regulation of cellular attachment to basement membranes 
via laminin.  It was identified as a genotoxic responsive protein (167). Its expression level 
in L929 cells was elevated 3 fold after X-irradiation. How this protein might function in 
cancer drug resistance is not clear and needs further investigation.
Higher abundance of prohibitin
      Prohibitin (spot 34) was found to be more abundant in MCF-7/MX cell than control 
MCF-7 cells. Prohibitin is a 30 kDa protein, evolutionarily conserved in a variety of 
organisms (168). It is mainly located in the inner membrane of mitochondria, and is 
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recruited into nucleus in response to genotoxic stress (169-170). Mutations of prohibitin 
have been found in breast cancer cells (168). Prohibitin has also been reported to play a 
protective role in breast cancer cell lines treated with chemotherapeutic agents. 
Comparing the parental UMSCC10b head and neck carcinoma cell line and the 5.9-fold 
cisplatin-resistant subline, UMSCC10b/Pt-S15, by mRNA levels, prohibitin has been 
shown to be up-regulated in association with cisplatin resistance (171). It has also been 
shown stable over-expression of prohibitin in a human B cell line blocks apoptosis 
induced by the topoisomerase I inhibitor camptothecin(172).  It appears to play an 
important role in determining the chemosensitivity of the cells. How prohibitin interacts 
with the established cell death pathway to regulate response to chemotherapeutic drugs is 
not clear. It may be a cell survival or anti-apoptotic factor (173-174).
Higher abundance of mitotic checkpoint protein BUB 3
      Mitotic checkpoint protein BUB 3 (spot 77) is more abundant in MCF-7/AdrVp than 
in control MCF-7 cells. Its abundance in MCF-7/VP, MCF-7/MX is the same as that in 
control MCF-7 cells. Mitotic checkpoint protein BUB3 plays an important role in mitotic 
spindle checkpoint, “a signal transduction based surveillance mechanism that ensures the 
fidelity of cell division by preventing the premature advance of cells from metaphase to 
anaphase prior to the successful attachment of kinetochores to spindle microtubules 
(spindle assembly)” (175). This control functions to ensure the chromosomes are intact 
and that crucial steps of the cell cycle are completed before the following step is initiated. 
Improper spindle formation causes M arrest until the defect is fixed. Mitotic checkpoint 
3, together with two other checkpoint proteins BUB1 and BUB2, has been observed to be 
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overexpressed in gastric cancer. For MCF-7 cancer cells under genotoxic stress caused by 
chemotherapeutic agents, the higher abundance of mitotic protein BUB 3 may mean 
enhancement of this checkpoint in cell cycle, allowing enough time for DNA repair and 
cytoskeleton assembly, resulting in the fixation of the defects caused by the drug.
Higher abundance of the 70 kDa glucose-regulated protein (GRP78)
GRP78 is found to be more abundant only in MCF-7/MX cells than in control MCF-7 
cells (4.91±0.46). It is a member of heat shock protein 70 (HSP70) family (178). It is a 
molecular chaperon localized in ER lumen (179). The presence of GRP78 in nucleus is 
mostly likely due to translocation after genotoxic stress (180). Interestingly, 
overexpression of GRP has been reported to be in association with drug resistance to 
chemotherapeutic drugs, such as adriamycin and etoposide(181-182). Its overexpression 
is also in association with the malignance of human breast tumors (183). It is well 
accepted that GRP78 is antiapoptotic, but how it interfere with apoptosis still needs 
further investigation (184-185). 
Higher abundance of cyclophilin B
Cyclophilin B (spot22) is found to be more abundant in the three drug resistant cell 
lines. It binds to a potent immunosuppressive drug, cyclosporine A (186).  It is a 
ubiquitous intracellular protein (187). It has been identified as a chaperone facilitating 
nuclear retrotransport (188). Further investigation is needed to study its role in drug 
resistance.
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     Overall, in the present research, we have found that MCF-7/VP, MCF-7/MX, MCF-
7/AdrVp cell lines have similar patterns of abundance changes in nuclear proteins with 
important differences. They all have lower abundances of cytoskeletal proteins. Besides 
this, MCF-7/VP and MCF-7/MX share more similarities. For example, changes in 
nucleolin and PARP-1 seem to be very important to deal with genotoxic stress and 
resisting cell death, and similar changes are observed in the two cell lines. Nucleolin level 
in MCF-7/AdrVp cells is about the same as those in control MCF-7 cells. PARP level in 
MCF-7/AdrVp is lower than that in control MCF-7 cells, but does not exceed the 
threshold of 2-fold that we set as significant change. An important cell cycle regulation 
protein, mitotic checkpoint protein BUB 3 is found to be more abundant only in MCF-
7/AdrVp. MCF-7/MX cells have been found to be cross-resistant to etoposide and 
adriamycin (10-fold). It should be pointed out that etoposide and mitoxantrone are both 
topoisomerase II poisons, sharing similar mechanisms of action to kill cancer cells. The 
cells resistant to these drugs, MCF-7/VP and MCF-7/MX cells have more similarities in 
nuclear abundance changes. 
Summary and prospectus
      Our objective is to contribute to the understanding of the mechanisms of drug 
resistance in cancer cells. Proteomics allows analysis of many proteins at once and 
narrows the targets for further investigation. Using proteomics approach, we have been 
able to identify some proteins whose changes of abundance correlate with drug resistance 
in MCF-7 breast cancer cells. These proteins are actively involved in chromatin structure, 
DNA repair, cell cycle regulation and protein folding. This is the first indication that most 
of them are related to drug resistance. The results support the hypothesis that drug 
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resistance in cancer cells is a multifactorial process. Many proteins are involved, although 
one or a few proteins may play a dominant role. Different sets of proteins may be 
involved to deal with different genotoxic assaults.
      The present research has laid a foundation for further study of nuclear proteins in 
MCF-7 cells. A new method of protein pre-fractionation, liquid isoelectrofocusing, is 
being developed and implemented in our lab. This will enable us to analyze low-abundant 
nuclear proteins in MCF-7 cells. In combination with other biology techniques, such as 
chromatin immuniprecipitation, more nuclear proteins which are involved in drug 
resistance can be revealed.
       The proteins which alter in abundance in drug resistant cells need to be further 
investigated. Over-expression or gene silencing can be used to test their roles in drug 
resistance. Once their roles are confirmed, they can be exploited as biomarkers for 
diagnosis of development of drug resistance. New strategies may be developed to kill the 
cancer cells using these proteins as novel drug targets.
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